J. Jaime Caro
Jaime advances Evidera’s leadership in developing and applying novel techniques in simulation, health economics, epidemiology, and clinical trials. He is also professor in practice at the London School of Economics and professor of medicine, epidemiology, and biostatistics (adj) at McGill University.
Jaime continues to pioneer new methodologies. Recent work involves leveraging hybrid growth and decay functions to forecast highly local COVID-19 trajectories. As part of the IMPACT-HTA grant, he is working with colleagues at LSE, NICE and HAS on DICE 2.0, the new version of a unified approach to modeling that he created in 2016. This will enable rapid, standardized, and less error-prone development of forecasting models. This methodology is also being leveraged to create disease models, particularly in regenerative medicine, and it is being extended further to simulate the design of clinical trials. He has also applied the technique in simulated treatment comparison to provide comparative efficacy information in the absence of control arms. To provide an alternative to the well-known cost-per-QALY technique and avoid many of the latter’s problems, he is developing a broader approach to valuing health benefits, the BADI.
On behalf of the German health technology assessment agency, Jaime proposed an innovative approach to the assessment of health technologies, involving the efficiency frontier. As part of his work with governments, he has helped the World Bank Institute and the InterAmerican Court for Human Rights address the growing problem of Supreme Courts overriding health care system decisions and ordering them to provide treatments that had been considered unwarranted. After leading the ISPOR-SMDM Good Modeling Practices Task Force, Jaime also chaired the Quality Assurance for Modeling Studies Task Force. Jaime is co-chair of the ISPOR Science and Research Committee and has been awarded the Marilyn Dix Smith Leadership Award. In 2021, he will co-chair the ISPOR international meeting in Montreal.